AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
Sign Up to like & getrecommendations! Published in 2021 at "Advanced Science"
DOI: 10.1002/advs.202002922
Abstract: Abstract AZD9291 can effectively prolong survival of non‐small cell lung cancer (NSCLC) patients. Unfortunately, the mechanism of its acquired drug resistance is largely unknown. This study shows that autophagy and fibroblast growth factor receptor 1… read more here.
Keywords: azd9291; resistance reversal; crgd; resistance ... See more keywords
Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP-DRI-12.
Sign Up to like & getrecommendations! Published in 2022 at "Small"
DOI: 10.1002/smll.202204133
Abstract: The acquired resistance to Osimertinib (AZD9291) greatly limits the clinical benefit of patients with non-small cell lung cancer (NSCLC), whereas AZD9291-resistant NSCLCs are prone to metastasis. It's challenging to overcome AZD9291 resistance and suppress metastasis… read more here.
Keywords: metastasis; metastasis nsclc; azd9291 resistance; ahp dri ... See more keywords
SHR-A1403, a novel c-Met antibody-drug conjugate, overcomes AZD9291 resistance in NSCLC cells overexpressing c-Met.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer science"
DOI: 10.1111/cas.14180
Abstract: EGFR tyrosine kinase inhibitors (TKIs) have been used as the first-line treatment of non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations, while acquired resistance is ubiquitous and needs to be solved urgently. Here, we introduce… read more here.
Keywords: resistant cells; cells overexpressing; overexpressing met; resistance ... See more keywords